Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory

Wichy/Shutterstock.com

Halozyme Therapeutics Inc (HALO), based successful San Diego, California, is simply a pharmaceutical exertion institution that has built a high-margin, royalty-driven concern by transforming analyzable IV biologics into simple, accelerated subcutaneous injections. Its flagship ENHANZE level has revolutionized treatments specified arsenic DARZALEX SC, Phesgo, and VYVGART Hytrulo, cutting multi-hour crab and autoimmune therapies down to five-minute oregon patient-administerable doses.

This proprietary exertion provides Halozyme with a durable, annuity-like gross watercourse that is insulated from emblematic biotech R&D risk, portion offering important net visibility. The company’s royalty model, tied to blockbuster drugs crossed aggregate partners, is recurring, high-margin, and expected to perchance treble by 2028, with Adjusted EBITDA margins projected to emergence from 59–61% successful 2024 to 74–75% by 2028, reflecting operational leverage and superior discipline.

Halozyme’s maturation is further secured by an extended ENHANZE pipeline, ongoing IV-to-SC conversions, and beardown patent protection, which collectively guarantee continued royalty enlargement without reliance connected speculative cause development. The Hypercon acquisition enhances semipermanent durability by enabling ultra-concentrated biologics for at-home auto-injectors, extending Halozyme’s intelligence spot into the 2040s and positioning it arsenic a captious enabler of decentralized, AI-assisted healthcare. This dual-platform strategy amplifies diligent autonomy, improves attraction efficiency, and aligns Halozyme with the aboriginal of personalized biologics.

While risks see patent expiration, litigation, spouse concentration, and the eventual 2030–2035 gross cliff, Halozyme’s predictable, high-margin model, combined with a robust exertion moat and disciplined execution, underpins a compelling concern case. With EPS projected to accelerate and royalties expanding, the institution is positioned for beardown net growth, making it a high-quality mid-cap compounder with a $75–$90 terms people by 2026.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted its CRISPR cistron editing leadership, high-margin Casgevy therapy, beardown organization backing, and near-term objective catalysts. CRSP’s banal terms has appreciated by astir 30.5% since our coverage. 24K Research shares a akin presumption but emphasizes Halozyme Therapeutics’ (HALO) recurring, royalty-driven gross and patent-protected ENHANZE platform.